Literature DB >> 8808594

Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains.

M C Willing1, S P Deschenes, R L Slayton, E J Roberts.   

Abstract

Nonsense and frameshift mutations, which predict premature termination of translation, often cause a dramatic reduction in the amount of transcript from the mutant allele (nonsense-mediated mRNA decay). In some genes, these mutations also influence RNA splicing and induce skipping of the exon that contains the nonsense codon. To begin to dissect how premature termination alters the metabolism of RNA from the COL1A1 gene, we studied nonsense and frameshift mutations distributed over exons 11-49 of the gene. These mutations were originally identified in 10 unrelated families with osteogenesis imperfecta (OI) type 1. We observed marked reduction in steady-state amounts of mRNA from the mutant allele in both total cellular and nuclear RNA extracts of cells from affected individuals, suggesting that nonsense-mediated decay of COL1A1 RNA is a nuclear phenomenon. Position of the mutation within the gene did not influence this observation. None of the mutations induced skipping of either the exon containing the mutation or, for the frameshifts, the downstream exons with the new termination sites. Our data suggest that nonsense and frameshift mutations throughout most of the COL1A1 gene result in a null allele, which is associated with the predictable mild clinical phenotype, OI type 1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8808594      PMCID: PMC1914787     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  37 in total

1.  Improved downward capillary transfer for blotting of DNA and RNA.

Authors:  Y Z Ming; X Di; E P Gomez-Sanchez; C E Gomez-Sanchez
Journal:  Biotechniques       Date:  1994-01       Impact factor: 1.993

2.  Diverse mutations in patients with Menkes disease often lead to exon skipping.

Authors:  S Das; B Levinson; S Whitney; C Vulpe; S Packman; J Gitschier
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

3.  Mammalian nonsense codons can be cis effectors of nuclear mRNA half-life.

Authors:  P Belgrader; J Cheng; X Zhou; L S Stephenson; L E Maquat
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

4.  A nonsense mutation and exon skipping in the Fanconi anaemia group C gene.

Authors:  R A Gibson; A Hajianpour; M Murer-Orlando; M Buchwald; C G Mathew
Journal:  Hum Mol Genet       Date:  1993-06       Impact factor: 6.150

5.  mRNA surveillance by the Caenorhabditis elegans smg genes.

Authors:  R Pulak; P Anderson
Journal:  Genes Dev       Date:  1993-10       Impact factor: 11.361

6.  Impact of premature stop codons on mRNA levels in infantile Sandhoff disease.

Authors:  Z X Zhang; N Wakamatsu; E H Mules; G H Thomas; R A Gravel
Journal:  Hum Mol Genet       Date:  1994-01       Impact factor: 6.150

7.  Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen.

Authors:  M C Willing; S P Deschenes; D A Scott; P H Byers; R L Slayton; S H Pitts; H Arikat; E J Roberts
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

8.  Marfan syndrome as a paradigm for transcript-targeted preimplantation diagnosis of heterozygous mutations.

Authors:  Z A Eldadah; J A Grifo; H C Dietz
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

9.  Nonsense but not missense mutations can decrease the abundance of nuclear mRNA for the mouse major urinary protein, while both types of mutations can facilitate exon skipping.

Authors:  P Belgrader; L E Maquat
Journal:  Mol Cell Biol       Date:  1994-09       Impact factor: 4.272

10.  Nuclear retention of COL1A1 messenger RNA identifies null alleles causing mild osteogenesis imperfecta.

Authors:  D A Redford-Badwal; M L Stover; M Valli; M B McKinstry; D W Rowe
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

View more
  37 in total

1.  The spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-mammary syndrome.

Authors:  M Bamshad; T Le; W S Watkins; M E Dixon; B E Kramer; A D Roeder; J C Carey; S Root; A Schinzel; L Van Maldergem; R J Gardner; R C Lin; C E Seidman; J G Seidman; R Wallerstein; E Moran; R Sutphen; C E Campbell; L B Jorde
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

2.  Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.

Authors:  P A Dawson; J C Marini
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

3.  Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.

Authors:  G Grassi; A Forlino; J C Marini
Journal:  Nucleic Acids Res       Date:  1997-09-01       Impact factor: 16.971

Review 4.  The collagenopathies: review of clinical phenotypes and molecular correlations.

Authors:  Rebekah Jobling; Rohan D'Souza; Naomi Baker; Irene Lara-Corrales; Roberto Mendoza-Londono; Lucie Dupuis; Ravi Savarirayan; L Ala-Kokko; Peter Kannu
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

5.  Deletions in HOXD13 segregate with an identical, novel foot malformation in two unrelated families.

Authors:  F Goodman; M L Giovannucci-Uzielli; C Hall; W Reardon; R Winter; P Scambler
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

6.  The Human Collagen Mutation Database 1998.

Authors:  R Dalgleish
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

Review 7.  Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.

Authors:  Joan C Marini; Antonella Forlino; Wayne A Cabral; Aileen M Barnes; James D San Antonio; Sarah Milgrom; James C Hyland; Jarmo Körkkö; Darwin J Prockop; Anne De Paepe; Paul Coucke; Sofie Symoens; Francis H Glorieux; Peter J Roughley; Alan M Lund; Kaija Kuurila-Svahn; Heini Hartikka; Daniel H Cohn; Deborah Krakow; Monica Mottes; Ulrike Schwarze; Diana Chen; Kathleen Yang; Christine Kuslich; James Troendle; Raymond Dalgleish; Peter H Byers
Journal:  Hum Mutat       Date:  2007-03       Impact factor: 4.878

Review 8.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

9.  Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta.

Authors:  Joel R Chamberlain; David R Deyle; Ulrike Schwarze; Peirong Wang; Roli K Hirata; Yi Li; Peter H Byers; David W Russell
Journal:  Mol Ther       Date:  2007-10-23       Impact factor: 11.454

10.  Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships.

Authors:  Dale L Bodian; Ting-Fung Chan; Annie Poon; Ulrike Schwarze; Kathleen Yang; Peter H Byers; Pui-Yan Kwok; Teri E Klein
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.